ArticleClinical epidemiology2025

Post-Marketing Safety Concerns with Efgartigimod alfa: A Pharmacovigilance Analysis Based on the Food and Drug Administration Adverse Event Reporting System Database.

Jinlong Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.